It is the first such combination to be approved by the Drugs Controller General of India (DCGI) and has completed a multi-centre clinical trial data on Indian patients, Dr Reddy's stated in a press release.
The Atorvastatin market is currently valued at Rs 300 crore and is growing at over 34 per cent annually. The Ramipril market is about Rs 145 crore, growing at over 15 per cent annually, the company said.
The new product is available in two fixed dose combinations of Atocor-R 2.5 (Atorvastatin 10 mg + Ramipril 2.5 mg ) and Atocor-R 5 (Atorvastatin 10 mg + Ramipril 5 mg) and comes in packs of 10.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app